TY - JOUR
T1 - Effect of antidepressants on striatal and accumbens extracellular dopamine levels
AU - Ichikawa, Junji
AU - Meltzer, Herbert Y.
N1 - Funding Information:
The research reported was supported in part by USPHS MH 41684, GCRC MO1RR00080 and the National Alliance for Research on Schizophrenia and Depression (NARSAD) as well as grants from the Elisabeth Severance Prentiss Foundation and Mitton and Tamar Maltz. H.Y.M. is the recipient of a USPHS Research Career Scientist Award MH 47808. We are grateful to Mr. Jose A. Garcia and Mr. Michael T. Kitchen for an excellent technical assistance and to Ms. Lee Mason for an excellent secretarial assistance.
PY - 1995/8/15
Y1 - 1995/8/15
N2 - The effect of the selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitor, fluoxetine (10 mg/kg s.c.), two tricyclic antidepressants, clomipramine (10 mg/kg s.c.) and imipramine (10 mg/kg s.c.), and vehicle on extracellular dopamine levels was studied in rat nucleus accumbens and striatum by in vivo microdialysis. Fluoxetine produced significant decreases in extracellular dopamine levels in both the nucleus accumbens and striatum (mean maximum percentage decrease: 58% and 57% of pre-drug baseline, respectively). In contrast, imipramine and clomipramine significantly increased extracellular dopamine in the striatum (148% and 150%, respectively) compared to the effect of vehicle alone (118%). These results suggest that the selective serotonin reuptake inhibitor, fluoxetine, and the tricyclic antidepressants, clomipramine and imipramine, affect dopaminergic activity in diverse ways and in a region-specific manner. Thus, the antidepressant effect of these drugs is unlikely to be related to their acute effects on dopaminergic neurotransmission. The differential effects of the selective serotonin reuptake inhibitor and tricyclic antidepressants on extracellular dopamine could account for other differences in their clinical and side effect profiles. Further studies of the chronic effects of the selective serotonin reuptake inhibitor and the tricyclic antidepressants on dopaminergic activity are required to elucidate the role of dopamine in the antidepressant effect.
AB - The effect of the selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitor, fluoxetine (10 mg/kg s.c.), two tricyclic antidepressants, clomipramine (10 mg/kg s.c.) and imipramine (10 mg/kg s.c.), and vehicle on extracellular dopamine levels was studied in rat nucleus accumbens and striatum by in vivo microdialysis. Fluoxetine produced significant decreases in extracellular dopamine levels in both the nucleus accumbens and striatum (mean maximum percentage decrease: 58% and 57% of pre-drug baseline, respectively). In contrast, imipramine and clomipramine significantly increased extracellular dopamine in the striatum (148% and 150%, respectively) compared to the effect of vehicle alone (118%). These results suggest that the selective serotonin reuptake inhibitor, fluoxetine, and the tricyclic antidepressants, clomipramine and imipramine, affect dopaminergic activity in diverse ways and in a region-specific manner. Thus, the antidepressant effect of these drugs is unlikely to be related to their acute effects on dopaminergic neurotransmission. The differential effects of the selective serotonin reuptake inhibitor and tricyclic antidepressants on extracellular dopamine could account for other differences in their clinical and side effect profiles. Further studies of the chronic effects of the selective serotonin reuptake inhibitor and the tricyclic antidepressants on dopaminergic activity are required to elucidate the role of dopamine in the antidepressant effect.
KW - (Rat)
KW - 5-HT (5-hydroxytryptamine, serotonin)
KW - Antidepressant
KW - Clomipramine
KW - Dopamine
KW - Extrapyramidal symptom
KW - Fluoxetine
KW - Imipramine
KW - Microdialysis, in vivo
KW - Nucleus accumbens
KW - Striatum
UR - http://www.scopus.com/inward/record.url?scp=0029114750&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029114750&partnerID=8YFLogxK
U2 - 10.1016/0014-2999(95)00264-L
DO - 10.1016/0014-2999(95)00264-L
M3 - Article
C2 - 8521908
AN - SCOPUS:0029114750
SN - 0014-2999
VL - 281
SP - 255
EP - 261
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 3
ER -